Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT)-论文-万方医学网

Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT)

导出原文传递

翻译打印收藏纠错

作者： Bacorro, Warren ^[1] ; Baldivia, Kathleen ^[2] ; Dumago, Mark ^[3] ; Bojador, Maureen ^[4] ; Milo, Abigail ; Trinidad, Celestine Marie ; Mariano, Jocelyn ; Gonzalez, Gil ; Ortin, Teresa Sy

作者单位： Dept Radiat Oncol,Univ Santo Tomas Hosp ^[1] Dept Radiol,Univ Santo Tomas Hosp ^[2] Dept Anat Pathol,Univ Santo Tomas Hosp ^[3] Gynecol Oncol Unit,Univ Santo Tomas Hosp ^[4]

关键词 Cervical cancer intensity-modulated radiotherapy simultaneous integrated boost nodal boost hypofractionation QUALITY-OF-LIFE RADIATION-THERAPY EUROPEAN-ORGANIZATION CONCURRENT CHEMOTHERAPY AMERICAN BRACHYTHERAPY CONSENSUS GUIDELINES ONCOLOGY-GROUP LYMPH-NODES CISPLATIN TOXICITY

发布时间 2022-07-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT)

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT)

相似文献

相关期刊

检索历史清除